Invention Grant
- Patent Title: RTP801L siRNA compounds and methods of use thereof
- Patent Title (中): RTP801L siRNA化合物及其使用方法
-
Application No.: US13651123Application Date: 2012-10-12
-
Publication No.: US08614311B2Publication Date: 2013-12-24
- Inventor: Elena Feinstein , Igor Mett , Hagar Kalinski
- Applicant: Quark Pharmaceuticals, Inc.
- Applicant Address: US CA Fremont
- Assignee: Quark Pharmaceuticals, Inc.
- Current Assignee: Quark Pharmaceuticals, Inc.
- Current Assignee Address: US CA Fremont
- Agency: Cooper & Dunham LLP
- Agent John P. White
- Main IPC: C07H21/04
- IPC: C07H21/04
Abstract:
The invention provides chemically modified siRNA oligonucleotides that target RTP801L, compositions comprising same and to the use of such molecules to treat, inter alia, respiratory diseases including acute and chronic pulmonary disorders, eye diseases including glaucoma and ION, microvascular disorders, angiogenesis- and apoptosis-related conditions, and hearing impairments.
Public/Granted literature
- US20130131143A1 RTP801L SIRNA COMPOUNDS AND METHODS OF USE THEREOF Public/Granted day:2013-05-23
Information query
